Feasibility and safety of cellular therapy for in-utero repair of myelomeningocele (CuRe Trial): a first-in-human, phase 1, single-arm study.

Farmer DL, Kumar P, Reynolds E, Lee SY, Powne AB, Pivetti CD, Zwienenberg M, McLennan AS, Nolta JA, Brown EG, Saadai P, Hirose S, Wang A.

Open source

DOI: 10.1016/s0140-6736(25)02466-3
Published: 2026-02-01
Container: Lancet
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s0140-6736-25-02466-3,
  title = {Feasibility and safety of cellular therapy for in-utero repair of myelomeningocele (CuRe Trial): a first-in-human, phase 1, single-arm study.},
  author = {Farmer DL and  Kumar P and  Reynolds E and  Lee SY and  Powne AB and  Pivetti CD and  Zwienenberg M and  McLennan AS and  Nolta JA and  Brown EG and  Saadai P and  Hirose S and  Wang A.},
  year = {2026},
  journal = {Lancet},
  doi = {10.1016/s0140-6736(25)02466-3},
  url = {https://doi.org/10.1016/s0140-6736(25)02466-3}
}

RIS

TY  - JOUR
TI  - Feasibility and safety of cellular therapy for in-utero repair of myelomeningocele (CuRe Trial): a first-in-human, phase 1, single-arm study.
AU  - Farmer DL
AU  -  Kumar P
AU  -  Reynolds E
AU  -  Lee SY
AU  -  Powne AB
AU  -  Pivetti CD
AU  -  Zwienenberg M
AU  -  McLennan AS
AU  -  Nolta JA
AU  -  Brown EG
AU  -  Saadai P
AU  -  Hirose S
AU  -  Wang A.
PY  - 2026
JO  - Lancet
DO  - 10.1016/s0140-6736(25)02466-3
UR  - https://doi.org/10.1016/s0140-6736(25)02466-3
ER  -

APA

DL, F., P, K., E, R., SY, L., AB, P., CD, P., M, Z., AS, M., JA, N., EG, B., P, S., S, H., & A., W. (2026). Feasibility and safety of cellular therapy for in-utero repair of myelomeningocele (CuRe Trial): a first-in-human, phase 1, single-arm study.. Lancet. https://doi.org/10.1016/s0140-6736(25)02466-3

Source records

europe-pmc · retrieved 2026-09-27T09:53:19.850Z